Rapid Dose Therapeutics Corp. (DOSE.CN)
CAD 0.18
(-10.0%)
CAD 0.18
(-10.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.04 Million CAD | 2.57% |
| 2022 | 4.91 Million CAD | 74.56% |
| 2021 | 2.81 Million CAD | -47.97% |
| 2020 | 5.41 Million CAD | 22.0% |
| 2019 | 4.43 Million CAD | 126.92% |
| 2018 | 1.95 Million CAD | 6453.81% |
| 2017 | 29.83 Thousand CAD | -20.96% |
| 2016 | 37.75 Thousand CAD | 60.29% |
| 2015 | 23.55 Thousand CAD | -17.92% |
| 2014 | 28.69 Thousand CAD | -2.3% |
| 2013 | 29.36 Thousand CAD | -32.16% |
| 2012 | 43.29 Thousand CAD | -18.78% |
| 2011 | 53.3 Thousand CAD | 348.57% |
| 2010 | 11.88 Thousand CAD | -50.64% |
| 2009 | 24.07 Thousand CAD | 381.52% |
| 2008 | 5000.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.47 Million CAD | 6.85% |
| 2024 Q1 | 5.12 Million CAD | 1.55% |
| 2023 Q4 | 5.04 Million CAD | -22.77% |
| 2023 Q3 | 6.52 Million CAD | 10.01% |
| 2023 Q2 | 5.93 Million CAD | 11.77% |
| 2023 Q1 | 5.31 Million CAD | 8.01% |
| 2023 FY | 5.04 Million CAD | 2.57% |
| 2022 Q3 | 4.16 Million CAD | 9.85% |
| 2022 Q4 | 4.91 Million CAD | 18.12% |
| 2022 FY | 4.91 Million CAD | 74.56% |
| 2022 Q1 | 3.26 Million CAD | 15.76% |
| 2022 Q2 | 3.78 Million CAD | 16.23% |
| 2021 Q1 | 3.05 Million CAD | -43.64% |
| 2021 Q2 | 2.69 Million CAD | -11.71% |
| 2021 Q3 | 2.32 Million CAD | -13.63% |
| 2021 Q4 | 2.81 Million CAD | 21.06% |
| 2021 FY | 2.81 Million CAD | -47.97% |
| 2020 Q2 | 5.15 Million CAD | 10.99% |
| 2020 Q3 | 5.68 Million CAD | 10.35% |
| 2020 Q4 | 5.41 Million CAD | -4.84% |
| 2020 FY | 5.41 Million CAD | 22.0% |
| 2020 Q1 | 4.64 Million CAD | 4.68% |
| 2019 Q4 | 4.43 Million CAD | 12.75% |
| 2019 FY | 4.43 Million CAD | 126.92% |
| 2019 Q1 | 1.65 Million CAD | -15.44% |
| 2019 Q3 | 3.93 Million CAD | 131.8% |
| 2019 Q2 | 1.69 Million CAD | 2.67% |
| 2018 Q1 | 114.61 Thousand CAD | -18.03% |
| 2018 FY | 1.95 Million CAD | 6453.81% |
| 2018 Q4 | 1.95 Million CAD | 293.68% |
| 2018 Q3 | 496.74 Thousand CAD | 807.6% |
| 2018 Q2 | 54.73 Thousand CAD | -52.25% |
| 2017 FY | 29.83 Thousand CAD | -20.96% |
| 2017 Q1 | 17.67 Thousand CAD | 13.5% |
| 2017 Q2 | 29.83 Thousand CAD | 68.86% |
| 2017 Q3 | 33.59 Thousand CAD | 12.58% |
| 2017 Q4 | 139.83 Thousand CAD | 316.25% |
| 2016 Q2 | 37.75 Thousand CAD | 60.15% |
| 2016 Q3 | 36.9 Thousand CAD | -2.25% |
| 2016 Q4 | 15.56 Thousand CAD | -57.81% |
| 2016 Q1 | 23.57 Thousand CAD | 3.99% |
| 2016 FY | 37.75 Thousand CAD | 60.29% |
| 2015 Q2 | 23.55 Thousand CAD | 525.19% |
| 2015 FY | 23.55 Thousand CAD | -17.92% |
| 2015 Q3 | 21.3 Thousand CAD | -9.52% |
| 2015 Q4 | 22.66 Thousand CAD | 6.38% |
| 2015 Q1 | 3767.00 CAD | -28.6% |
| 2014 Q3 | 10.42 Thousand CAD | -63.68% |
| 2014 Q1 | 76.04 Thousand CAD | 14.55% |
| 2014 FY | 28.69 Thousand CAD | -2.3% |
| 2014 Q4 | 5276.00 CAD | -49.38% |
| 2014 Q2 | 28.69 Thousand CAD | -62.27% |
| 2013 Q2 | 29.36 Thousand CAD | -5.11% |
| 2013 Q1 | 30.94 Thousand CAD | 8.45% |
| 2013 FY | 29.36 Thousand CAD | -32.16% |
| 2013 Q4 | 66.39 Thousand CAD | 48.98% |
| 2013 Q3 | 44.56 Thousand CAD | 51.74% |
| 2012 Q4 | 28.53 Thousand CAD | -19.81% |
| 2012 Q1 | 26.44 Thousand CAD | -35.31% |
| 2012 Q2 | 43.29 Thousand CAD | 63.73% |
| 2012 Q3 | 35.58 Thousand CAD | -17.8% |
| 2012 FY | 43.29 Thousand CAD | -18.78% |
| 2011 Q1 | - CAD | -100.0% |
| 2011 Q3 | 34.84 Thousand CAD | -34.62% |
| 2011 Q4 | 40.87 Thousand CAD | 17.29% |
| 2011 FY | 53.3 Thousand CAD | 348.57% |
| 2011 Q2 | 53.3 Thousand CAD | 0.0% |
| 2010 Q3 | 18.66 Thousand CAD | 57.06% |
| 2010 FY | 11.88 Thousand CAD | -50.64% |
| 2010 Q2 | 11.88 Thousand CAD | 315.63% |
| 2010 Q1 | 2859.00 CAD | -63.19% |
| 2010 Q4 | 1832.00 CAD | -90.18% |
| 2009 Q3 | 6419.00 CAD | -73.34% |
| 2009 Q4 | 7767.00 CAD | 21.0% |
| 2009 FY | 24.07 Thousand CAD | 381.52% |
| 2009 Q2 | 24.07 Thousand CAD | 0.0% |
| 2008 FY | 5000.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 2.71 Million CAD | -85.425% |
| Asep Medical Holdings Inc | 3.05 Million CAD | -65.247% |
| BetterLife Pharma Inc. | 8.02 Million CAD | 37.122% |
| BioVaxys Technology Corp. | 3.48 Million CAD | -44.687% |
| ChitogenX Inc. | 6.71 Million CAD | 24.864% |
| Defence Therapeutics Inc. | 4.06 Million CAD | -24.154% |
| Entheon Biomedical Corp. | 85.32 Thousand CAD | -5810.411% |
| Gemina Laboratories Ltd. | 3.04 Million CAD | -65.811% |
| Glow Lifetech Corp. | 2.34 Million CAD | -114.954% |
| Lexston Life Sciences Corp. | 39.86 Thousand CAD | -12549.219% |
| Pharmala Biotech Holdings Inc. | 1.02 Million CAD | -390.088% |
| Doseology Sciences Inc. | 82.49 Thousand CAD | -6013.462% |
| MYND Life Sciences Inc. | 5.77 Million CAD | 12.669% |
| Nova Mentis Life Science Corp. | 841.66 Thousand CAD | -499.186% |
| PharmaTher Holdings Ltd. | 252.9 Thousand CAD | -1894.107% |
| PreveCeutical Medical Inc. | 5.95 Million CAD | 15.379% |
| Telescope Innovations Corp. | 1.35 Million CAD | -273.28% |